Individual Assignment 4A - Aisyah Nuralam 29123362
Individual Assignment 4A - Aisyah Nuralam 29123362
Case 1:
The following financial data contains Apple Inc. revenue between 2015 - 2023 from different regions
and ASTRA International income, financial position, ratio analysis and other information for the years
2018 and 2022. Estimate the significant reportable segments.
1
ASTRA International income, financial position, ratio analysis and other information for the years 2018
and 2022.
2
Answer :
Segments 2015 2016 2017 2018 2019 2020 2021 2022 2023
Americas 93.8 86.6 96.6 112 116.9 124.5 153.3 169.6 162.5
Europe 50.3 49.8 54.9 62.4 60.2 68.6 89.3 95.1 94.2
China 58.7 48.5 51.6 51.9 43.6 40.3 68.3 74.2 72.5
Japan 15.7 16.9 15.3 21.7 21.5 21.4 28.4 25.9 24.2
Asia Pacific 15 13.6 14.1 17.4 17.8 19.6 26.3 29.3 29.6
Total 233.5 215.4 232.5 265.4 260 274.4 365.6 394.1 383
Significant 202.8 184.9 203.1 226.3 220.7 233.4 310.9 338.9 329.2
75% rule 175.125 161.55 174.375 199.05 195 205.8 274.2 295.575 287.25
The estimation of the significant reportable segment was done by putting the country as the
segments and then summing up each of the country’s revenue. The next step was to calculate the
10% of the total revenue, or better known as the 10% rule. After finding out the 10% of the total
revenue, we then determine which segments are not a significant revenue in that particular year. To
validate the significance of the other segments, we use 75% rules, which is to multiply the total
revenue that year to 75%. Then, sum up the significant revenue. The significance was valid if the
total significant revenue is more than the 75% of the total revenue.
In this case, after calculating and validating the significance of the segments, it shows that the
revenue from Asia-Pacific and Japan are not significant to Apple’s total revenue because it’s below
10% of the total revenue. And the significant revenue, which are from the Americas, Europe, and
China, are valid because the total of that revenue is more than 75% of the total revenue.
3
Based on Estimation of the significant reportable segments from ASTRA International if we divide it
into the segment of years it showed that all of the operation activities are significantly contributed
to ASTRA. This conclusion was taken after calculating the result of 10K Requirement and the 75% are
passed.
Case 2:
Carefully read through this auditor report [ https://www.aramco.com/-
/media/publications/corporate-reports/annual-reports/saudi-aramco-ara-2022-english.pdf (page
148-155)] and analyze different opinions of auditor about company’s going concern, matter of
emphasis, and lack of consistency in accounting in financial reporting.
Answer :
- The auditor explicitly mentions their responsibility to assess the Group’s ability to continue as a
going concern. This assessment involves considering the Board of Directors' judgements, disclosures,
and the going concern basis of accounting.
- Opinion: Some may agree with the auditor’s assessment, given their independence and adherence
to auditing standards. Others might question the thoroughness of the assessment or raise concerns
about undisclosed factors that could affect the company’s ability to continue as a going concern.
2. Matters of Emphasis:
- The auditor identifies two key audit matters: assessment of the recoverability of goodwill and
brand recognized as part of an acquisition and accounting for a significant transaction involving gas
pipelines.
- Opinion: Stakeholders may appreciate the transparency provided by the auditor in highlighting
these key audit matters, as they represent significant areas of judgement and potential risk.
However, some might question what other potential areas of concern were not highlighted.
- The auditor explains the accounting treatment for a significant transaction involving the sale of
a 49% equity interest in Aramco Gas Pipelines Company and the recognition of the upfront sale
proceed as a non-controlling interest
- Opinion: While the auditor provides a detailed explanation of the accounting treatment, some
stakeholders may question the consistency of this treatment with industry standards or previous
practices. They might seek further clarification on why alternative treatments were not considered.
NIM : 26123362